论文部分内容阅读
目的:探讨沙格列汀联合二甲双胍对2型糖尿病的疗效与安全性。方法:选取200例2型糖尿病患者,按随机数字表法分为两组,沙格列汀组(102例)口服沙格列汀联合二甲双胍治疗,阿卡波糖组(98例)口服阿卡波糖联合二甲双胍治疗。通过观察并记录治疗前后糖代谢情况与体重指数水平,SF-36量表各项评分,治疗期间不良反应情况,评价沙格列汀联合二甲双胍对2型糖尿病的疗效与安全性。结果:治疗后,两组HbAlc,BMI,FBG,2hPBG水平均明显下降(P<0.05),且沙格列汀组患者HbAlc,BMI,FBG,2 hPBG水平明显低于阿卡波糖组(P<0.05);治疗后3个月两组患者SF-36表各项评分均明显提高(P<0.05),但两组间差异没有统计学意义(P>0.05);随访期间,两组不良反应率相比,差异没有统计学意义(P>0.05)。结论:沙格列汀联合二甲双胍可以明显控制患者血糖水平,减轻患者体重,提高患者生活质量用药安全性好,值得临床推广使用。
Objective: To investigate the efficacy and safety of saxagliptin and metformin in type 2 diabetes mellitus. Methods: Two hundred and twenty patients with type 2 diabetes mellitus were selected and randomly divided into two groups according to the random number table. The saxagliptin group (102 cases) was treated with oral saxagliptin and metformin. The acarbose group (98 cases) Wave sugar combined with metformin treatment. The effect and safety of saxagliptin and metformin on type 2 diabetes mellitus were evaluated by observing and recording the status of glucose metabolism and body mass index before and after treatment, the scores of SF-36 scale and the adverse reactions during treatment. Results: After treatment, the levels of HbAlc, BMI, FBG and 2hPBG decreased significantly in both groups (P <0.05), and the levels of HbAlc, BMI, FBG and 2 hPBG in the saxagliptin group were significantly lower than those in the acarbose group <0.05). SF-36 scores in both groups were significantly increased at 3 months after treatment (P <0.05), but there was no significant difference between the two groups (P> 0.05). During the follow-up period, two groups of adverse reactions The difference was not statistically significant (P> 0.05). Conclusion: Saxagliptin combined with metformin can significantly control the patient’s blood glucose levels, reduce body weight and improve the quality of life of patients with good drug safety, worthy of clinical promotion and use.